Brokerages Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $19.50

by · The Cerbat Gem

enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) has been given an average rating of “Moderate Buy” by the eight brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $19.50.

A number of research firms have issued reports on ENGN. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of enGene in a research note on Monday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of enGene in a research note on Tuesday, October 14th. Finally, Morgan Stanley cut their target price on shares of enGene from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, September 12th.

View Our Latest Report on enGene

enGene Trading Down 7.3%

NASDAQ ENGN opened at $7.33 on Monday. enGene has a 12 month low of $2.65 and a 12 month high of $9.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.34 and a quick ratio of 10.34. The company has a market capitalization of $375.22 million, a price-to-earnings ratio of -3.86 and a beta of -0.27. The company’s fifty day moving average price is $6.71 and its two-hundred day moving average price is $4.74.

enGene (NASDAQ:ENGN – Get Free Report) last posted its quarterly earnings results on Thursday, September 11th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06). As a group, research analysts predict that enGene will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of enGene

A number of hedge funds have recently modified their holdings of ENGN. PFS Partners LLC bought a new position in shares of enGene during the 3rd quarter worth approximately $61,000. Paloma Partners Management Co bought a new position in enGene in the second quarter valued at about $38,000. Affinity Asset Advisors LLC bought a new stake in shares of enGene during the second quarter worth about $280,000. Cresset Asset Management LLC bought a new stake in shares of enGene during the second quarter worth about $36,000. Finally, Adage Capital Partners GP L.L.C. lifted its stake in shares of enGene by 2.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company’s stock worth $7,041,000 after acquiring an additional 41,874 shares during the period. 64.16% of the stock is currently owned by institutional investors and hedge funds.

About enGene

(Get Free Report)

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

Featured Articles